Search

Copyright of Current Retina Journal / Güncel Retina Dergisi is the property of Anadolu Kitabevi Basim Yayim Medikal Turizm Kirtasiye Tic. Ltd. Sti. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Current Retina Journal / Güncel Retina Dergisi is the property of Anadolu Kitabevi Basim Yayim Medikal Turizm Kirtasiye Tic. Ltd. Sti. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of MN Opthalmology / MN Oftalmoloji is the property of Medical Network and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of MN Opthalmology / MN Oftalmoloji is the property of Medical Network and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Purpose To investigate the effect of posterior vitreous detachment (PVD) on aflibercept response in treatmentnaïve diabetic macular oedema (DME). Design A retrospective cohort study. Methods One hundred and fifty eyes of 150 treatmentnaïve patients with DME were enrolled. The patients were divided into three groups according to their PVD status: group 1 (no PVD during injections), group 2 (PVD during injections) and group 3 (PVD already present initially). Three consecutive aflibercept injections at intervals of 1 month were applied to all patients. The efficacy of the aflibercept treatment on DME was assessed by comparing changes in central retinal thickness (CRT) and bestcorrected visual acuity (BCVA) values after three loading dose injections. Results After three consecutive injections, the mean reduction of CRT in groups 1, 2 and 3 were -199.6±106.9, -224.9±124.1 and -210.7±126.3, respectively. The decrease in CRT was significant in all groups (p<0.001 in all groups, paired-samples t-test); however, mean changes in CRT were similar among groups (all p>0.05, one-way analysis of variance (ANOVA)). The mean improvement in BCVA in groups 1, 2 and 3 was 6.6±0.9, 6.5±0.8 and 6.1 ±0.4 ETDRS letters, respectively. The improvement of BCVA was significant in all groups (p<0.001 in all groups, paired-samples t-test) and mean changes were similar between groups (p>0.05, one-way ANOVA). There was no significant relationship between the presence or development of PVD and the mean decrease of CRT and improvement of BCVA (for CRT r=-0.052, p=0.531 and for BCVA r=-0.078, p=0.342). Conclusion In the present study, it was observed that the efficacy of aflibercept treatment in patients with DME did not depend on PVD status. [ABSTRACT FROM AUTHOR]

Copyright of MN Opthalmology / MN Oftalmoloji is the property of Medical Network and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Purpose: To investigate the effect of age on Ranibizumab (Lucentis®) response in treatment-naive diabetic macular edema. Materials and methods: One hundred seventy six eyes of 176 treatment-naive patients with macular edema secondary to Diabetes Mellitus were enrolled in this study. The patients in the study were divided into the following four groups according to their ages: group 1 (40-50 years), group 2 (51-60 years), group 3 (61-70 years), and group 4 (>70 years). Three consecutive injections at intervals of 1 month were applied to all diabetic patients. The efficacy of the ranibizumab treatment on macular edema according to age groups was assessed by optical coherence tomography (OCT) by comparing the central foveal thickness (CFT) and mean visual acuity (VA) changes after initial and three loading dose injections. Results: After three consecutive ranibizumab injection, the mean reduction of CFT in groups 1, 2, 3, and 4 were -255.1±123.4, -205.8±99.8, -194.6±119.1, and -191.8±105.7μm, and mean improvement of VA in groups 1, 2, 3, and 4 were 6.1±0.9, 4.9±0.7, 4.2±0.2, 3.8±0.3 letters respectively. The improvement of VA and reduction of CFT was significantly different in each group (p<0.001 in all groups, Paired-samples t-test). The changes of CFT and VA was significantly different between age groups (p:0.025 and p:0.009 respectively, Analysis of Covariance, ANCOVA). Additionally, ages of patients were correlated with the mean reduction of CFT and mean improvement of VA for the whole study group (r:-0.150, p:0.047 for CFT, r:-0.756, p<0.001 for VA, Pearson correlation). Conclusion: In this study, it was observed that the efficacy of ranibizumab treatment was found to be more effective in younger patients in treatment-naive diabetic macular edema patients. [ABSTRACT FROM AUTHOR]

A 46-year-old man presented to our clinic with a chest trauma during a car traffic accident 2 hours ago and a complaints of decreased visual acuity more pronounced in left eye. The patient's visual acuity was 20/32 on the right and hand motion on the left eye. On the fundus examination, yellow-white patch-like lesions, tiny retinal hemorrhages and macular edema were observed bilaterally, more prominent in left eye. The patient was diagnosed with Purtscher's retinopathy based on absence of head trauma, associated retinal findings, and assisted imaging methods. In this case report, it is aimed to present the diagnosis and treatment outcome of the patient with improved optical coherence tomography (OCT) and fundus fl uorescein angiography (FFA) imaging methods with dramatic visual enhancement in the short term with early systemic steroid therapy. To the best of our knowledge, this is the first reported case of Purtscher's retinopathy, which is the treatment that started in the earliest period literature. [ABSTRACT FROM AUTHOR]